EGFR-homing double-stranded RNA vector for systemic cancer treatment
AssigneeAlexander Levitzki
InventorsAlexander Levitzki, Alexei Shir
Life of this patent
Estimating the term…
Abstract
An epidermal growth factor receptor (EGFR)-homing vector comprising a double-stranded RNA (dsRNA) molecule with an EGFR-binding peptide or polypeptide, is disclosed for use in combination with immune cells for treatment of cancer overexpressing EGFR.
Claims2
A pharmaceutical composition for systemic administration comprising a pharmaceutically acceptable carrier and an EGFR-homing vector selected from the group consisting of a vector comprising polyinosinic-polycytidylic acid double stranded RNA;
- unbranched polyethyleneimine covalently linked to polyethylene glycol;
- and mEGF (pIC/PPE) and a vector comprising polyinosinic-polycytidylic acid double stranded RNA;
- unbranched polyethyleneimine covalently linked to polyethylene glycol;
- and peptide GE11 (pIC/PPGE11).
An EGFR-homing vector selected from the group consisting of a vector comprising polyinosinic-polycytidylic acid double stranded RNA;
- unbranched polyethyleneimine covalently linked to polyethylene glycol;
- and mEGF (pIC/PPE) and a vector comprising polyinosinic-polycytidylic acid double stranded RNA;
- unbranched polyethyleneimine covalently linked to polyethylene glycol;
- and peptide GE11 (pIC/PPGE11).
Dependencies are inferred from the claim text.